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Abstract
Background—Prostate cancer survivors with a rising prostate specific antigen (PSA) level have 
few treatment options, experience a heightened state of uncertainty about their disease trajectory 
that might include the possibility of cancer metastasis and death, and often experience elevated 
levels of distress as they have to deal with a disease they thought they had conquered. Guided by 
self-regulation theory, the present study examined the cognitive and affective processes involved 
in shared decision making between physician and patients who experience a rising PSA after 
definitive treatment for prostate cancer.
Methods—In-depth interviews were conducted with 34 prostate cancer survivors who had been 
diagnosed with a rising PSA (i.e., biochemical failure) within the past 12 months. Survivors were 
asked about their experiences and affective responses after being diagnosed with a rising PSA and 
while weighing potential treatment options. In addition, patients were asked about their decision-
making process for the initial prostate cancer treatment.
Results—Compared to the initial diagnosis, survivors with a rising PSA reported increased 
negative affect following their diagnosis, concern about the treatability of their disease, increased 
planning and health behavior change, heightened levels of worry preceding doctor’s appointments 
(especially prior to the discussion of PSA testing results), and a strong reliance on physicians’ 
treatment recommendations.
Conclusions—Prostate cancer survivors’ decision-making processes for the treatment of a 
rising PSA are markedly different from those of the initial diagnosis of prostate cancer. Because 
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patients experience heightened distress and rely more heavily on their physicians’ 
recommendations with a rising PSA, interactions with the health care provider provide an 
excellent opportunity to address and assist patients with managing the uncertainty and distress 
inherent with rising PSA levels.
Introduction
Despite advances in prostate cancer treatment and favorable five-year survival rates, a 
growing number of prostate cancer survivors experience a rise in prostate specific antigen 
(PSA) levels without evidence of widespread disease (e.g., metastases to other sites). A 
rising PSA refers to an elevated PSA level after initial prostate cancer treatment (1). The 
widespread use of PSA testing for the detection of prostate cancer has resulted in a 
substantial shift in detection of the disease such that an increasing number of men are 
diagnosed and treated with clinically localized disease at a younger age (2,3) and eventually 
are more likely to experience a disease recurrence. It has been estimated that 40% of patients 
initially treated with surgery or radiation will eventually experience rising PSA levels, 
resulting in approximately 60,000 new cases per year (4,5). A rising PSA in this instance 
suggests recurrence of the cancer, although it might take months or even years to manifest 
clinically. During this time, most survivors are asymptomatic until bone metastases, which 
are associated with increased levels of pain, are detected through a scan.
Although multiple treatment options are available to survivors with a rising PSA, there is 
little agreement on a definitive or uniform approach to treatment as there is insufficient data 
to guide treatment recommendations. Existing data on the efficacy of various treatment 
options are sparse and derived primarily from single institution studies or retrospectively 
analyzed data sets (6). Most physicians recommend careful monitoring of PSA levels, 
especially in the early stages of a rising PSA. Intermittent or traditional hormone treatment 
is the most commonly chosen approach, although external-beam radiation and salvage 
prostatectomy are also available. The choice of one of these options is usually determined by 
clinical factors shown to influence progression from biochemical failure to metastatic 
disease (7–9). These factors include: PSA doubling time, PSA velocity, time of PSA 
recurrence, pathologic stage, Gleason score of the initial tumor at diagnosis, and presence of 
recurrent disease on biopsy after radiation treatment.
Based on such clinical factors, patients and their physicians ideally evaluate available 
options and balance the potential benefits of treatment with possible side effects (e.g., for 
hormone treatment: loss of libido, hot flashes, loss of lean muscle mass, etc.) that negatively 
impact a patient’s quality of life. The difficulty patients face in making a treatment decision 
is often compounded by inconsistent physician recommendations for patients with a rising 
PSA (10,11) and by elevated levels of distress caused by the realization that the disease they 
thought they had conquered is returning, very likely leading to metastatic disease and 
eventually to death (12). Thus, physicians and patients face a complex array of factors in 
deciding which treatment pathway, if any, to pursue. Although much research has examined 
treatment decision making among prostate cancer patients at initial diagnosis (e.g., 10–12), 
no prior studies have identified the decision-making processes at this later stage of the 
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disease trajectory (13–15). The goal of the present study was to examine these factors by 
qualitatively interviewing patients during the time of a rising PSA diagnosis.
Guided by self-regulation theory (16,17), our interview approach emphasized the 
importance of both cognitive and affective factors influencing information processing and 
decision making. Cognitive processes include patients’ representations of prostate cancer, 
such as their perceptions and beliefs about the causes of the disease, its consequences on 
quality of everyday life, and its treatability. The simultaneously occurring affective distress 
arising from the uncertainties of the efficacy of treatment, its impact on quality of life, and 
its potential efficacy in extending life add an additional layer of factors impacting the 
decision-making process (18). Because of the uncertainty and emotional distress 
surrounding a rising PSA diagnosis, it is possible that patients strongly rely on physicians’ 
counsel and recommendations. The main objective of the present study was to engage 
patients in a detailed retrospective and comparative examination of the processes involved in 
making treatment decisions following their initial diagnosis of prostate cancer as well as the 
recent diagnosis of a rising PSA.
Methods
Participants and Recruitment
Eligible participants for this study were prostate cancer survivors who were treated for early 
stage disease, had been diagnosed with biochemical failure within the past 12 months 
(indicating a possible recurrence), were not castrate resistant, and were able to provide 
informed consent and speak and understand English well enough to complete the interviews. 
Biochemical failure for surgical patients was defined as two consecutive PSA measurements 
of ≥ 0.2ng/mL after a nadir of < 0.1ng/mL (7,19,20). Failure for radiation patients was 
defined by criteria set by the ASTRO consensus panel (1997) of three consecutive elevations 
of the PSA level after a stable nadir, independent of baseline level. All survivors were 
recruited through their treating physicians (i.e., urologists or oncologists) at major medical 
centers in the New York metropolitan area between January 2011 and December 2011. After 
patients expressed interest and consented to the study, they completed a baseline 
questionnaire, which was distributed prior to their scheduled appointment. The Institutional 
Review Boards (IRBs) of all participating institutions approved this study.
Procedures
The patients providing the current interview data were a simple random sample of 
participants from a longitudinal study involving data collection at four time points (3, 6, 9, 
and 12 months) following a diagnosis of a rising PSA. Patients were included regardless of 
the time and kind of treatments they had (e.g., surgery alone, or surgery followed by a 
course of radiation treatment) prior to the diagnosis of a rising PSA. Patients were 
personally interviewed at two possible study mile-stones: 1) once they made a treatment 
decision to address their rising PSA, or 2) at the end of the 12-month study period if the 
patient continued to be monitored but no treatment decisions had been made. Interviews 
were conducted until thematic saturation occurred (i.e., no new themes or topics emerged).
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Interviews
A random sample of 42 patients from the larger study sample (n=125) were approached to 
participate in a follow-up phone interview. Of those approached, 34 patients participated, 
resulting in an 80% recruitment rate and a sub-sample that represented 27.2% of the entire 
study sample. Phone interviews averaged 25 to 30 minutes in length. Structured interview 
guides were developed based on our self-regulation theoretical framework, with an emphasis 
on cognitive and affective processes that have been shown to influence decision making. All 
interviews were conducted by a trained psychologist (MD).
Interviews were comprised of three main parts. The first part of the interview focused on 
patients’ initial prostate cancer diagnosis and initial treatment decision. Patients were asked 
about the circumstances of their initial diagnosis, how they decided on their initial treatment 
(including the physician’s role in discussing prognosis and decision making), experiences 
with treatment and potential side effects, and whether they experienced any continued 
urinary or sexual problems. Patients were also asked about their initial emotional reaction to 
the diagnosis.
The second part of the interview addressed patients’ concerns about their rising PSA levels. 
Patients were asked about their emotional state after they heard that their PSA levels were 
rising, whether they thought much about the rising PSA levels, how they made sense of it 
(i.e., causes, consequences, where it comes from), what they thought could be done about 
their rising PSA, and what their priorities and goals were in dealing with the condition. 
When appropriate, patients were probed for negative emotions and experiences following 
their diagnoses.
The third part of the interview focused on patients’ treatment options, especially hormone 
therapy (i.e., androgen deprivation therapy; ADT) and salvage radiation therapy. Patients 
were asked whether they knew when they would begin treatment, which factors prompted 
them to do something about their rising PSA (if they had), and how long it took them to 
make their decision (if they already made a decision). Patients were also asked what 
information and resources contributed to their decision making, including the physicians’ 
role in decision making. Finally, patients were asked about the emotional impact of the new 
diagnosis of rising PSA. Because this “watch and see” approach of monitoring PSA levels is 
a valid treatment choice, all patients were asked the same questions regardless of whether 
they had made a decision to start active treatment. The interview concluded by thanking 
participants for their time and dedication to the study.
Data Analysis
All interviews were audio-recorded, transcribed by a professional transcription service, and 
validated by study investigators to ensure accurate and complete transcription. A 
theoretically derived preliminary coding sheet was developed to aid in the coding of 
answers. Two members of the study staff read all transcribed interviews and coded 
responses based on this coding sheet. New codes were added if both coders agreed on their 
necessity. Initial inter-rater reliability indicated moderate agreement between the two coders 
with a Cohen’s Kappa of .58 for the entire interview from the full sample. The coders then 
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discussed and resolved their coding discrepancies and achieved perfect agreement (Cohen’s 
Kappa = 1.0).
Results
Sample Characteristics
Pertinent patient demographics and clinical characteristics are summarized in Table 1 and 
the coded themes are summarized in Table 2. A detailed description and discussion of 
themes follows.
Reactions to a Rising PSA Diagnosis: Negative Affect and Optimism
A majority of patients reported experiencing higher levels of negative affect when told their 
PSA was rising compared to the time when they were initially diagnosed with prostate 
cancer. Specifically, patients reported disappointment, discouragement, worry, and fear of 
death.
“Well you know my first reaction was disappointed…obviously I go through a 
major surgery and then you find out that it worked to a point, but it was something 
that wasn’t complete. So the first few months I wasn’t really angry or depressed, I 
was disappointed.” [Patient 209]
“I felt disturbed and crazy…I was already hurt by it [rising PSA] …” [Patient 229]
“Now, trying to figure out this maze, that I got cancer, you know – you’re gonna – 
the first thing you think of is, ‘I’m gonna die’…you know, or your life’s 
shortened.” [Patient 215]
Although patients with a rising PSA reported feeling more worried, fearful, and 
disappointed than they did at initial diagnosis, they also reported being more grateful to be 
alive and expressed optimism about the future.
“I got a positive outlook on life and that’s…I think it helps me.” [Patient 215]
“I am optimistic too. I know [we have talked to] the best doctor.” [Patient 20]
The expressed optimism appears to help patients cope with their current situation and might 
counteract negative emotions that were present when they found out that their PSA started to 
rise. Whereas fighting the disease was often of utmost importance at the initial diagnosis, 
most patients expressed acceptance of their situation and being more aware about their 
potentially limited future. This translated into new plans for the foreseeable future:
“I’m spending more, traveling more, and donating more to charity at a faster pace 
than I might have otherwise. So I’ve kind of sped up my time horizon on doing 
things that I want to do while I can do it.” [Patient 224]
“But it also can be triggered by decisions about even silly things, like 401k plans 
and retirement. ‘What am I saving for?’ Other kinds of unusual situations force you 
to sort of reframe your future.” [Patient 201]
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Processing Diagnosis: Belief about Treatability of Disease
The changes among patients to engage in actively planning and being more accepting of 
their situation may have been a consequence of the realization that their cancer was no 
longer curable. At initial diagnosis, most patients believed their initial treatment would be 
successful. Not one patient reported thinking their cancer would be fatal or would return 
post-treatment at the time of initial diagnosis. However, once diagnosed with a rising PSA, 
some patients expressed beliefs about the fatality of their condition. Specifically, patients 
focused on the potential incurability of their disease.
“In thinking back [to initial diagnosis] I don’t know that I put the cancer label on it. 
It was just I had a bad prostate, they took it out, and I got on with my life.” [Patient 
238]
“Now I am very nervous about it because I was sure we could take care of it, but 
now I’m no longer sure they can take care of it.” [Patient 29]
“I’m no longer considered cured. I was considered cured, I felt, for that first year. 
But now that we’ve had our chemical recurrence, I feel what I would say is I’m in 
remission, I’m not cured, and anything could happen at any time and we just have 
to closely monitor it.” [Patient 36]
“Well, I know that I have – or I’m pretty sure I have metastatic disease…I know 
that I have biochemical recurrence.” [Patient 208]
The Role of Follow Up Appointments: Promoting Worry
Although many patients reported being worried about their rising PSA levels and the 
possible recurrence of cancer, they did not report thinking about it on a daily basis. Rather, 
patients stated that they predominantly worried about their rising PSA levels only when 
prompted by a physician visit to get their PSA levels tested. Patients’ positive feelings 
seemingly served as a buffer against stress and anxiety; however, worry returned when they 
were visiting their physician to check on their PSA levels. This is consistent with past 
research indicating that physician visits serve as “worry promoters” among cancer patients 
(21).
“But at this point every time I go for a PSA test the week or ten days before the test 
I notice that I’m becoming more tense, more irritable, more distracted, and until I 
hear the results I may stay that way.” [Patient 32]
“I don’t ruminate about cancer all the time. It’s just on occasion, you know, 
especially on going back to the check-ups to remind you when you walk into a 
cancer hospital about who you really are.” [Patient 201]
“You know it’s like I go, I am at ease, and then I know I have to go for a blood test, 
when the time comes for that blood test, I start getting nervous again, and I get 
nervous, you know, until I see the results on the computer.” [Patient 01]
This worry expressed prior to follow-up appointments that monitored rising PSA levels 
might prompt some patients to develop action plans. For instance, patients reported that 
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being worried about their cancer’s progression actually motivated them to live better lives 
and enjoy their lives more.
“Well, I know that I have – or I’m pretty sure I have metastatic disease…I know 
that I have biochemical recurrence. I don’t know exactly how I deal with it. I think 
I can deal with it a lot of different ways. One is, I try to accept the fact that life is 
finite. I try to live as well as I can.” [Patient 208]
Decision Making Processes: Monitoring PSA Levels and the Role of the Physician
A distinct feature of being diagnosed with a rising PSA was that patients were not offered 
multiple treatment options. Rather, they had the choice between monitoring their PSA levels 
and deciding when to go on hormone therapy. Perhaps due to the unique features of decision 
making during this phase, most patients reported being concerned with tracking their PSA 
levels upon receiving a diagnosis of a rising PSA. They tracked and compared their own 
PSA levels to pre-designated “milestones,” such as the time it took for a value to double or 
certain upper limits upon which treatment would be initiated. Patients’ perceptions of such 
values were not necessarily medically accurate or based on physician recommendations 
(e.g., PSA above 10). However, there is no gold standard cut-off PSA value to initiate 
hormone treatment, thus patients adopted physicians’ suggestions or invented their own 
“rules” on what is considered a cut-off for PSA levels.
“I think there’s a cut off [for PSA levels] of 4.0.” [Patient 204]
“Well, I mean, it’s in the back of my head if it gets to a certain point, they didn’t 
give me a specific number, but I would assume if it went, like, 1 or 2 that would be 
quite an increase.” [Patient 220]
“So it [PSA level] is going to somewhere around 9 or 10, when it gets to that point, 
we will probably do the hormone therapy.” [Patient 20]
Perhaps due to the unique nature of the limited number of options with rising PSA versus 
initial diagnosis as well as the developed relationship with their treating physician, patients 
relied much more heavily on their physicians’ recommendations in making a treatment 
decision upon receiving a diagnosis of a rising PSA. At initial diagnosis, many patients 
described themselves as having an independent and active voice in treatment decisions. 
They also reported seeking second opinions.
“I decided that surgery was probably the most surest way of attacking it and feeling 
comfortable.” [Patient 260]
“After the diagnosis…I went to get a second opinion.” [Patient 234]
In contrast, patients reported relying on their physicians’ advice more after they had been 
diagnosed with a rising PSA than they did at initial diagnosis. In fact, more patients with a 
rising PSA made their treatment decision based solely on their physician’s preferences or 
advice than at initial diagnosis.
“I would just go and do whatever she [the doctor], you know, whatever she would 
suggest.” [Patient 205]
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“And the decisions have been easy because I much more put myself in [the 
doctor’s] hands.” [Patient 208]
There are several reasons why patients may have relied on physician recommendations for 
treatment decisions with rising PSA levels. First, most patients reported having strong 
positive feelings toward their physicians:
“…if she tells me to fly to the moon, I’d fly to the moon. I’m in love with that 
woman [the doctor].” [Patient 238]
Second, patients explicitly reported trusting their physicians’ skills and opinions.
“You put your hands in people who understand fully and better than you exactly 
what the best course of action to take and you accept that.” [Patient 260]
“It was a world-class doctor. He was published. He came out of [university], so I 
felt confident in his background.” [Patient 201]
Third, it seemed that patients happily transferred decision-making responsibilities to their 
physicians.
“…I feel comfortable with the decisions that we’ve made and I trust [the doctor] 
and the care that he has given me, so I will continue with that.” [Patient 3001]
“I have a lot of confidence in both of them [doctors], in particular [the doctor] with 
whom I’ve had much more contact. And I would actually pretty much leave it in 
their, in his hands to decide if going to hormone therapy were either necessary or 
appropriate.” [Patient 32]
Discussion
The present study provides new insight into decision-making processes that occur among 
prostate cancer survivors with rising PSA levels, an increasing large segment of cancer 
survivors (4,5). As expected and in accord with self-regulation theory (16,17), the data 
suggest that both patient-based cognitive and affective processes and interpersonal processes 
(i.e., the physician-patient relationship) shape the decision-making processes. Specifically, 
results indicated the three most distinct features of the decision-making processes upon 
diagnosis of a rising PSA are: 1) patients’ experience an increase in negative affect and 
worry and are also more skeptical of the curability of their disease, 2) follow-up 
appointments during which patients’ PSA levels are monitored are triggers for increasing 
worry and anxiety surrounding their prognosis, and 3) patients rely heavily on their 
physicians during the decision-making process. These three main findings suggest that 
physicians ought to be attuned to patients’ increased emotionally vulnerability upon 
receiving this diagnosis; be aware that follow-up appointments, even though considered 
routine, will likely exacerbate distress; and know that they play a crucial role in 
recommending treatment options and guiding patients through the treatment decision-
making process. These results are discussed in detail below within a cognitive and affective 
processes framework.
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Cognitive Processes
As expected, patients with a rising PSA level were more skeptical of their treatment being 
curative than they were at initial diagnosis (13). The shift in the perception of many prostate 
cancer patients from believing that their cancer was curable following the initial treatment to 
realizing that the cancer has returned following a diagnosis of rising PSA, was associated 
with a marked change in the perception of control over their cancer (22). This change in 
illness perception was associated with changes in patients’ action plans, such as changes in 
everyday behavior including increased spending and saving less money, and attempts to 
enjoy life more. These are all indications of the assumption that life will be shorter than 
previously expected
In addition to reporting they were no longer cured, patients also reported that they closely 
monitored their PSA levels and compared them to a “cutoff” or doubling rate. These values, 
however, were not always medically accurate. This suggests that physicians may want to 
provide medically accurate targets to patients, even in the absence of gold standards, in 
order to increase their understanding of the disease and its time trajectory. Additionally, 
although gold standards for PSA levels do not exist, most urologists would provide ADT for 
a rising PSA, especially if the PSA is rapidly increasing. Prior treatment, however, may 
factor into which options are available to patients (e.g., radiation patients are unlikely to 
have further radiation). As such, physicians should incorporate these concerns into treatment 
option discussions with patients.
Affective Processes
Patients also reported feeling disappointed, discouraged, or fearful upon being diagnosed 
with a rising PSA level. Despite this increase in negative affect, patients with rising PSA 
levels also reported being hopeful, optimistic, and happy to be alive. The presence of 
positive affect is an indication of acceptance of the situation and the desire to enjoy life 
despite the specter of a worsening disease. In short, patients did not seem to let worry and 
distress influence their day-to-day activities. Rather, patients reported feeling worried 
predominately prior to check-up visits where they would receive results of their PSA tests, a 
finding previously reported for breast cancer survivors (21). Heightened affective processes 
are likely to influence disease and treatment-relevant information processing and by 
extension treatment decision making through compromised processing and integration of 
information (23). Supporting this conclusion, prostate cancer patients have listed emotions 
as more reliable and valuable in treatment decisions than risk-based information (24).
Physician-Patient Relational Processes
Perhaps the most unique finding from the present study is that patients relied more heavily 
on their physicians’ recommendations when making treatment decisions for a rising PSA 
than they did at initial diagnosis. Whereas many patients at initial diagnosis get second 
opinions (25) and reported doing so in the present study, some patients with rising PSA 
levels reported relying solely on their physicians’ advice in making treatment decisions. In 
the present study, patient-physician relationships ranged from patients having known their 
current physician for up to 18 years to being referred to them upon receiving a diagnosis of a 
rising PSA. Despite length of relationship, many patients reported full reliance on their 
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physicians’ opinions and recommendations, underscoring the important role that physicians 
play in decision making in this situation.
The present study does not provide sufficient data to fully explain this shift in decision 
making behavior. However, patients indicated that relying on their physicians’ 
recommendations reduced the amount of burden they felt in making a decision about 
treatment. It is certainly possible that some patients, after having dealt with the disease for a 
number of years, felt ready to turn over “responsibility” for their disease to their physician, 
effectively experiencing decision fatigue. Moreover, patients may have relied more on their 
physicians’ recommendations because the treatment options were less varied than they were 
at initial diagnosis or because they viewed the physicians’ recommendations (to go on 
hormone therapy or keep monitoring PSA levels) as less severe than other options such as 
surgery. Future research should examine why there is a major shift in how much patients 
rely on their physicians’ recommendations when diagnosed with a rising PSA versus initial 
diagnosis.
These findings are in line with previous research which indicates that both the experience 
and stage of illness influence the degree to which patients desire to be involved in decision 
making surrounding their care (26). For instance, past research indicates that cancer patients 
whose condition had recently worsened were more likely to desire less involvement in 
decision making than those whose condition remained unchanged (27). Similarly, the 
present study found that once patients’ conditions had progressed with a rising PSA, they 
more frequently reported relying on physicians to aid in decision making. Health status has 
also been shown to influence patients’ desire for information. Several studies have shown 
that patients with severe illness may prefer to be less involved in decision making than 
patients with minor illnesses (26). As such, patients who face a more progressive and 
possibly more severe diagnosis than they did initially may desire less involvement in their 
treatment decision making.
Limitations and Directions for Future Research
The present study provides novel insight into the treatment decision-making processes of 
prostate cancer survivors diagnosed with rising PSA levels; however, it does have some 
limitations which must be considered in interpreting the results. One limitation is the 
retrospective description of patients’ treatment decision-making processes at initial 
diagnosis. Given that the average amount of time since initial diagnosis among this sample 
was approximately 9 years ago, it is possible that patients misremembered the cognitive, 
affective, or physician-patient relational processes that originally guided their treatment 
decision making. However, retrospective accounts of prostate cancer treatment decision 
making have been a common form of inquiry (14). The added advantage of asking patients 
to retrospectively recall their decision making is that it allows for a comparison of the same 
patient’s treatment decision making for a rising PSA rather than comparing two distinct 
groups to one another. Because emotional reactions attenuate over time leading to errors in 
recall of emotional experiences (28), it is possible that the more recent emotional reactions 
to rising PSA levels may be reported as higher than those associated with the initial 
diagnosis simply because less time has passed.
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Another limitation of the present study is that the data are qualitative and thus cannot be 
used to formally test hypotheses. Although qualitative data allows for exploration of themes 
and is hypothesis generating, it should be noted that the present sample was not 
representative of the majority of prostate cancer patients, which limits the generalizability of 
the data. Rather, the results from the present study provide a framework in which to continue 
developing and ultimately testing hypotheses using quantitative methods.
Another limiting factor of this study is that we did not fully probe all individuals for 
negative themes. For instance, some patients were probed about potential worry or 
uncertainty more deeply, when appropriate, but not all patients were asked about these 
potential concerns to the same extent.
Additionally, this study has limited generalizability given that the sample consisted of 
predominately White, well-educated men. Patient populations with lower levels of education 
may also exhibit lower levels of health literacy that, in turn, influences information 
processing and decision making. Future research should examine more racially and 
ethnically diverse samples as well as samples of individuals with lower levels of education 
to determine how these variables influence the decision-making processes of prostate cancer 
survivors with rising PSA levels.
Finally, another limitation of the present study is that the decision-making and physician-
patient relational processes examined in this study were only explored from the patient point 
of view. Examining these processes from the physician’s standpoint would add another layer 
of information that would be crucial in informing future intervention development. By 
examining the physicians’ attitudes and beliefs surrounding this situation, future research 
could create more targeted interventions to improve communication and shared decision 
making among patients and physicians.
Practice Implications
In short, patients’ reactions and decision making upon receiving a rising PSA diagnosis 
differed from those at the initial diagnosis across three broad themes. First, patients are 
likely to experience strong negative affect and are more skeptical about the treatability of 
their disease. Even if such feelings are not communicated to the consulting physician, health 
care providers need to be aware that patients are more emotionally vulnerable and 
potentially in need of support. A systematic review of physician-patient communication 
demonstrated that physicians’ abilities to communicate well with patients positively affected 
a multitude of patient outcomes, including emotional well-being, physical symptoms, and 
physiological measures (29). Thus, a physician’s ability to communicate empathically (e.g., 
acknowledging, praise, reassuring, encouraging; (30) with patients during this time will 
improve patients’ emotional and physical well-being and by extension improve information 
processing and decision making.
Second, follow-up appointments that are designed to monitor patients’ PSA levels often lead 
to high levels of worry and anxiety about the potential progression of their disease. Health 
care providers should be sensitive to the signs of distress and the psychosocial needs of their 
patients at this point in the disease trajectory. Physicians’ appointments with patients 
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diagnosed with a rising PSA provide an opportunity to respond to these psychological needs. 
PSA levels have been cited as a source of great uncertainty (and thus added worry and 
distress) for prostate cancer patients (31). Thus, patients might benefit from physicians 
providing a trajectory of how long to watch their PSA levels as well as giving them more 
certainty and information regarding criteria for taking action once a patient reaches a certain 
PSA level. These trajectories could be based on PSA doubling rates that have been shown to 
be effective in monitoring disease progression (32). Although providing guidelines might be 
helpful, focusing on addressing uncertainty and how to make decisions under uncertainty 
might be most helpful to patients with rising PSA levels.
Finally, patients rely heavily on their physicians for making decisions. This gives the health 
care provider a unique opportunity to introduce programs to support patients’ decision-
making processes as well as emotional well being. Specifically, physicians’ providing 
additional information could help reduce the burden of decision making that patients often 
face at this later point of their disease.
Conclusion
This study illustrates that decision-making processes vary depending on the time and nature 
of patients’ prostate cancer diagnoses. The present results highlight which components of 
the decision-making process are distinctly different for prostate cancer survivors diagnosed 
with a rising PSA compared to those at the time of initial cancer diagnosis. Given the 
differences in decision-making processes, it is important for physicians and other medical 
staff to be aware of the specific needs of patients at each stage. Understanding the increased 
role of importance that physicians play among prostate cancer survivors with rising PSA 
levels as well as the increased distress experienced by patients during follow up 
appointments could allow for better patient care, physician-patient communication, and 
support of needs. Ultimately, addressing the added distress from uncertainty surrounding 
rising PSA levels might improve patients’ outcomes, including quality of life and 
satisfaction with care.
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Table 1
Demographics and Clinical Characteristics.
Variable Mean/Percentage
Demographics
Average amount of time since initial diagnosis (SD) 9.18 years (5.49)
Average age (SD) 69.56 years (7.98)
Average length of marriage (SD) 34.27 years (14.94)
Race/ethnicity
 White 94%
 African-American 6%
Highest level of education completed
 High school degree 17.6%
 College degree 29.4%
 Post-graduate education 52.9%
Current employment
 Employed 52.9%
 Retired 44.1%
 Part-time employment 2.9%
Clinical Characteristics*
Average level of PSA at initial diagnosis (SD) 5.22 (4.70)
Initial treatment
 Surgery 58.8%
 External beam radiation therapy (EBRT) 20.6%
 Brachytherapy 5.9%
 Active surveillance 2.9%
 Did not report initial treatment decision 11.8%
*All clinical measures were self-report, so some data is missing or was not reported.
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